{"id":6345,"date":"2025-09-22T16:00:00","date_gmt":"2025-09-22T16:00:00","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=poster&#038;p=6345"},"modified":"2025-10-15T11:59:17","modified_gmt":"2025-10-15T11:59:17","slug":"sparsentan-sglt2i-iga-nephropathy-spartacus-phase2","status":"publish","type":"poster","link":"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/","title":{"rendered":"Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial"},"content":{"rendered":"\n\n<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"8001\" height=\"4501\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\"> Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"margin-top:calc(-150px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\" aria-hidden=\"true\"><\/i> Poster<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\" aria-hidden=\"true\"><\/i> Published on June 4, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics:<\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tContributors<br \/><span>Ayoub I, Tang S, Kooienga L et al.<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tPresented at: <br \/><span>ERA 2025<br \/>\r\nIIgANN 2025<br \/>\r\nGlomCon Hawaii 2025<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/medicalaffairs.travere.com\/wp-content\/uploads\/2025\/08\/ERA2025-Poster-SPARTACUS.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline\">View latest poster<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">\n\t\t\tShare: \n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fsparsentan-sglt2i-iga-nephropathy-spartacus-phase2%2F&#038;text=Sparsentan+%28SPAR%29+Added+to+Stable+Sodium-Glucose+Cotransporter-2+Inhibitors+%28SGLT2is%29+in+Adults+With+IgA+Nephropathy+%28IgAN%29+in+the+Phase+2+SPARTACUS+Trial\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fsparsentan-sglt2i-iga-nephropathy-spartacus-phase2%2F&#038;title=Sparsentan+%28SPAR%29+Added+to+Stable+Sodium-Glucose+Cotransporter-2+Inhibitors+%28SGLT2is%29+in+Adults+With+IgA+Nephropathy+%28IgAN%29+in+the+Phase+2+SPARTACUS+Trial\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fsparsentan-sglt2i-iga-nephropathy-spartacus-phase2%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Sparsentan%20%28SPAR%29%20Added%20to%20Stable%20Sodium-Glucose%20Cotransporter-2%20Inhibitors%20%28SGLT2is%29%20in%20Adults%20With%20IgA%20Nephropathy%20%28IgAN%29%20in%20the%20Phase%202%20SPARTACUS%20Trial&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fsparsentan-sglt2i-iga-nephropathy-spartacus-phase2%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\t\t<svg width=\"100%\" viewBox=\"0 0 1440 95\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"wave\">\r\n\t\t\t<path d=\"M0 94.883h1440v-55C971.349 142.422 479-88.172 0 39.828v55.055Z\" fill=\"#fff\"\/>\r\n\t\t<\/svg>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\"><div class=\"yoast-breadcrumbs\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span> \u00bb <span class=\"breadcrumb_last\" aria-current=\"page\">SPARTACUS: Concomitant Sparsentan and SGLT2i Use<\/span><\/span><\/div>\n\n\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-about-the-research\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">About the research<\/mark><\/span><\/h2>\n\n\n\n<div class=\"pdf-block\">\n\t\t\t\t<iframe src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/GlomCon2025-Presentation-SPARTACUS.pdf\" frameborder=\"0\"><\/iframe>\n\t\t<div class=\"pdf-block--buttons\">\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/GlomCon2025-Presentation-SPARTACUS.pdf\" class=\"btn\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"View\">View<\/a>\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/GlomCon2025-Presentation-SPARTACUS.pdf\" class=\"btn btn-outline\" download aria-label=\"Download\">Download<\/a>\n\t<\/div>\n<\/div>\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Summary<\/mark><\/span><\/h3>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Background<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li>Sparsentan is a non-immunosuppressive, <a href=\"https:\/\/medicalaffairs.travere.com\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noopener\">Dual Endothelin Angiotensin Receptor Antagonist (DEARA)<\/a> indicated to slow kidney function decline in adults with IgA nephropathy who are at risk for disease progression<sup>1-4<\/sup><\/li>\n<li>Treatment with sparsentan led to sustained proteinuria reduction and preservation of kidney function in the <a href=\"https:\/\/medicalaffairs.travere.com\/publications\/protect-2-year-results-sparsentan-vs-irbesartan-iga-nephropathy\/\" target=\"_blank\" rel=\"noopener\">Phase 3 PROTECT study<\/a><sup>3<\/sup><\/li>\n<li>In independent subgroup analyses from DAPA-CKD and EMPA-KIDNEY, sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced albuminuria and kidney disease progression in patients with IgA nephropathy<sup>5,6<\/sup><\/li>\n<li>An interim analysis of the Phase 2 SPARTACUS trial showed that in adults with IgA nephropathy receiving stable SGLT2i therapy, replacing renin-angiotensin system inhibitors (RASi) with sparsentan led to further reductions in albuminuria<sup>7<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-aim\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Aim<\/span><\/mark><\/h4>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br>To report final data from SPARTACUS, which evaluated the efficacy and safety of replacing RASi with sparsentan in adults with IgA nephropathy receiving stable SGLT2i therapy<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2447\" height=\"1260\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1.webp 2447w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-300x154.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-1024x527.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-768x395.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-1536x791.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-2048x1055.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/study-design_spartacus-1-290x149.webp 290w\" sizes=\"auto, (max-width: 2447px) 100vw, 2447px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\"><strong>Figure. Study design<sup>1<\/sup><\/strong><\/mark><br><br><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>SPARTACUS was a 24-week Phase 2, exploratory, open-label, single-arm, multicenter study of sparsentan when added to a stable SGLT2i in patients with IgA nephropathy at risk for disease progression.<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"resources\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Resources<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block feature-block--right\">\n\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1.webp\" class=\"a-img\" alt=\"Explore the SPARTACUS infographic\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1.webp 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1307-Travere-MA-Website-Header-PDP-5-V00-01-20240709-1-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--blue\">Downloadable Resource<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tExplore the SPARTACUS infographic\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/medicalaffairs.travere.com\/wp-content\/uploads\/2025\/09\/ERA2025-SPARTACUS-infographic.pdf\" target=\"_blank\" rel=\"noopener\" class=\"a-btn a-btn--secondary--blue\">\n\t\t\t\t\t\t\t\t\t\t<span>View<\/span>\n\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png\" class=\"a-img\" alt=\"Explore the SPARTACUS visual abstract\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--blue\">Downloadable Resource<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tExplore the SPARTACUS visual abstract\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/medicalaffairs.travere.com\/wp-content\/uploads\/2025\/09\/GlomCon2025-Visual-Abstract-SPARTACUS.pdf\" target=\"_blank\" rel=\"noopener\" class=\"a-btn a-btn--secondary--blue\">\n\t\t\t\t\t\t\t\t\t\t<span>View<\/span>\n\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-key-findings\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Key findings<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Replacing RASi with sparsentan in patients receiving stable SGLT2i treatment resulted in rapid and sustained reductions in proteinuria, with urine protein-creatinine ratio (UPCR) percentage decreasing by approximately 45% from baseline over 24 weeks<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-1-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Change in UPCR at each visit over 24 weeks<sup>1<\/sup><\/mark><\/strong><br><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Treatment with sparsentan and SGLT2i also led to rapid and sustained reductions in urine albumin-creatinine ratio (UACR), with a mean decrease of approximately \u201356% from baseline to Week 24, and nearly one-third of patients achieved UACR &lt;0.2 g\/g<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-2-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Percent of patients achieving UACR reduction endpoints at Week 24<sup>1<\/sup><\/mark><\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">eGFR remained relatively stable during the study following the replacement of RASi with sparsentan in patients receiving stable SGLT2i treatment<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V00-02-20250723_Graph-3-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Change in eGFR values at each visit over 24 weeks<sup>1<\/sup><\/mark><\/strong><br><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Adding sparsentan to a stable SGLT2i was generally well tolerated, with no unexpected safety signals<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The most common TEAEs included hypotension (n=7), headache (n=4), edema (n=4), peripheral edema (n=4), upper respiratory tract infection (n=3), and dizziness (n=3)<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1244\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-300x146.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-1024x497.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-768x373.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-1536x746.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-2048x995.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-SPARTACUS-PoDP-Ayoub-Images-V01-01-20250805_Patients-with-any-TEAE-290x141.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Table. Patients with any TEAE<\/mark><\/strong><br><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Read more about concomitant use of sparsentan and an SGLT2i in the <a href=\"https:\/\/medicalaffairs.travere.com\/posters\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"text-decoration-underline\">PROTECT open-label extension (OLE) study<\/span><\/a> and in a <a href=\"https:\/\/medicalaffairs.travere.com\/posters\/sparsentan-sglt2i-combination-igan-case-series\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"text-decoration-underline\">case series describing real-world experience<\/span><\/a><sup>8,9<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-conclusions\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Conclusions<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In patients with IgA nephropathy receiving stable SGLT2i therapy, switching from a maximally tolerated RASi to sparsentan resulted in rapid and sustained reductions in albuminuria and proteinuria, and achievement of UACR reduction endpoints<sup>1<\/sup><\/p>\n\n\n\n<p><br>Combination therapy with SGLT2i therapy and sparsentan was also well tolerated, with no unexpected safety signals<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong>\u00a0to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/poster\/6345#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center\" id=\"h-related-content\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"fw-600\">Related Content<\/span><\/mark><\/h4>\n\n\n  <div class=\"carousel-posts poster-carousel swiper carousel-type-poster wp-block-grizzly-posts-carousel\">\n    <div class=\"swiper-wrapper\">\n      <div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-combination-igan-case-series\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div>    <\/div>\n    <div class=\"swiper-pagination\"><\/div>\n          <\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Footnotes<\/mark><\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; OLE, open-label extension; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor; UACR, urine albumin-creatinine ratio; UPCR, urine protein-creatinine ratio.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Ayoub I et al. Presented at: European Renal Association 2025; June 4-7, 2025; Vienna, Austria.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci<\/em> (Lond). 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet.<\/em> 2023;402(10417):2077-2090.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Wheeler DC et al. <em>Kidney Int.<\/em> 2021;100(1):215-224.<\/li>\n\n\n\n<li class=\"has-small-font-size\">EMPA-KIDNEY Collaborative Group.<em> Lancet Diabetes Endocrinol.<\/em> 2024;12(1):51-60.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Ayoub I et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO849.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kooienga I et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO851.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Ravipati P et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO906.<\/li>\n<\/ol>\n<\/div>\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\"><br>MA-SP-25-0113 | September 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":6197,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","pdf_file_link":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/ERA2025-Poster-SPARTACUS.pdf"},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[198],"study_type":[176],"resource_type":[179,199,200,180],"class_list":["post-6345","poster","type-poster","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-spartacus","study_type-clinical","resource_type-infographic","resource_type-poster","resource_type-presentation","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SPARTACUS: Concomitant Sparsentan and SGLT2i Use in IgAN<\/title>\n<meta name=\"description\" content=\"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN\" \/>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial\" \/>\n<meta property=\"og:description\" content=\"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T11:59:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/\",\"name\":\"SPARTACUS: Concomitant Sparsentan and SGLT2i Use in IgAN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png\",\"datePublished\":\"2025-09-22T16:00:00+00:00\",\"dateModified\":\"2025-10-15T11:59:17+00:00\",\"description\":\"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png\",\"width\":8001,\"height\":4501,\"caption\":\"Tablet and pill bottle\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SPARTACUS: Concomitant Sparsentan and SGLT2i Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SPARTACUS: Concomitant Sparsentan and SGLT2i Use in IgAN","description":"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"en_US","og_type":"article","og_title":"Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial","og_description":"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN","og_url":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T11:59:17+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/","url":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/","name":"SPARTACUS: Concomitant Sparsentan and SGLT2i Use in IgAN","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png","datePublished":"2025-09-22T16:00:00+00:00","dateModified":"2025-10-15T11:59:17+00:00","description":"Summary of the final findings of the Phase 2 SPARTACUS study on the concomitant use of sparsentan and SGLT2i in IgAN","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-ASN-2024-Congress-Summary-V00-03-20240514.png","width":8001,"height":4501,"caption":"Tablet and pill bottle"},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-spartacus-phase2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"SPARTACUS: Concomitant Sparsentan and SGLT2i Use"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 11:03:34","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster\/6345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/poster"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/6197"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=6345"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=6345"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=6345"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=6345"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=6345"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=6345"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=6345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}